Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileHarold John Burstein, PH.D., M.D.

TitleAssociate Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
Yawkey 12th floor
450 Brookline Ave
Boston MA 02215
Phone617/632-2624
Fax617/632-1930
vCardDownload vCard (login for email)

Collapse Mentoring 
Collapse completed student projects
Defining the Health Care Needs for Breast Cancer Survivors PASTEUR
Summer, 06/25/01 - 08/17/01

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
U10CA180867     (BURSTEIN, HAROLD JOHN)May 19, 2014 - Feb 28, 2019
NIH/NCI
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
Role: Principal Investigator

U10CA032291     (BURSTEIN, HAROLD J.)Apr 1, 1982 - Mar 31, 2015
NIH/NCI
Cancer and Leukemia Group B
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 Aug 01; 28(8):1700-1712. PMID: 28838210.
    View in: PubMed
  2. Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, Gómez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perelló A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GF. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122. PMID: 28654365.
    View in: PubMed
  3. Wander SA, Mayer EL, Burstein HJ. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017 Sep 01; 35(25):2866-2870. PMID: 28580881.
    View in: PubMed
  4. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 Apr; 15(4):433-451. PMID: 28404755.
    View in: PubMed
  5. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 Apr 20; 35(12):1341-1367. PMID: 28148207.
    View in: PubMed
  6. Braun IM, Meyer FL, Gagne JJ, Nabati L, Yuppa DP, Carmona MA, Burstein HJ, Suzuki J, Nayak MM, Martins Y. Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study. Psychooncology. 2017 Aug; 26(8):1087-1092. PMID: 28040884.
    View in: PubMed
  7. Burstein HJ, Schrag D. Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? JAMA. 2017 01 03; 317(1):30-32. PMID: 27918782.
    View in: PubMed
  8. Vaz-Luis I, Burstein HJ. Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1399-1400. PMID: 27631400.
    View in: PubMed
  9. Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? Eur J Surg Oncol. 2016 Dec; 42(12):1780-1786. PMID: 27825710.
    View in: PubMed
  10. Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 Nov; 160(2):297-304. PMID: 27704226.
    View in: PubMed
  11. Mayer EL, Burstein HJ. Chemotherapy for Triple-Negative Breast Cancer: Is More Better? J Clin Oncol. 2016 Oct 01; 34(28):3369-71. PMID: 27551109.
    View in: PubMed
  12. Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 Aug; 159(1):151-62. PMID: 27484879.
    View in: PubMed
  13. Rugo HS, Rumble RB, Burstein HJ. Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. J Oncol Pract. 2016 Jun; 12(6):583-7. PMID: 27221996.
    View in: PubMed
  14. Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 Sep 01; 34(25):3069-103. PMID: 27217461.
    View in: PubMed
  15. Ma AD, Burstein HJ. Update in Hematology and Oncology: Evidence Published in 2015. Ann Intern Med. 2016 May 03; 164(9):W32-6. PMID: 27136229.
    View in: PubMed
  16. Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perelló A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 May 10; 34(14):1601-10. PMID: 27022111; PMCID: PMC4872319 [Available on 04/10/17].
  17. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar; 14(3):324-54. PMID: 26957618.
    View in: PubMed
  18. Burstein HJ, Lacchetti C, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. J Oncol Pract. 2016 Apr; 12(4):390-3. PMID: 26931400.
    View in: PubMed
  19. Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016 May 10; 34(14):1689-701. PMID: 26884586.
    View in: PubMed
  20. Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36. PMID: 26539793.
    View in: PubMed
  21. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec; 13(12):1475-85. PMID: 26656517.
    View in: PubMed
  22. Vaz-Luis I, Burstein HJ. With better adjuvant therapy, does breast cancer stage still matter? BMJ. 2015 Oct 06; 351:h5273. PMID: 26443566.
    View in: PubMed
  23. Mayer EL, Burstein HJ. Adjuvant endocrine therapy for postmenopausal women: Type and duration. Breast. 2015 Nov; 24 Suppl 2:S126-8. PMID: 26279133.
    View in: PubMed
  24. Mayer EL, Burstein HJ. Postmenopausal breast cancer: a best endocrine strategy? Lancet. 2015 Oct 03; 386(10001):1317-1319. PMID: 26211823.
    View in: PubMed
  25. Burstein HJ, Morrow M. Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy. N Engl J Med. 2015 Jul 23; 373(4):379-81. PMID: 26200984.
    View in: PubMed
  26. Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58. PMID: 26092816; PMCID: PMC4562429 [Available on 07/01/16].
  27. Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96. PMID: 25981899.
    View in: PubMed
  28. Reddy P, Blouin GC, Yeh YC, Burstein HJ. Choosing Treatments on the Basis of Cost: Can Clinicians Opt for Less Expensive Treatments? J Oncol Pract. 2015 Jul; 11(4):322-4. PMID: 25967907.
    View in: PubMed
  29. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):448-75. PMID: 25870381.
    View in: PubMed
  30. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. PMID: 25605863.
    View in: PubMed
  31. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41. PMID: 25564897; PMCID: PMC4313867.
  32. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46. PMID: 25495490; PMCID: PMC4341825.
  33. Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10; 32(35):3959-66. PMID: 25348000; PMCID: PMC4251959 [Available on 12/10/15].
  34. Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30. PMID: 25205424.
    View in: PubMed
  35. Regan MM, Walley B, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Rabaglio-Poretti M, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA1. PMID: 28141980.
    View in: PubMed
  36. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7. PMID: 24934787; PMCID: PMC4105484.
  37. Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014 Jul 01; 32(19):1979-86. PMID: 24888802; PMCID: PMC4879690.
  38. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50. PMID: 24888816; PMCID: PMC4076026.
  39. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18. PMID: 24881463; PMCID: PMC4175521.
  40. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20; 32(21):2255-69. PMID: 24868023; PMCID: PMC4876310.
  41. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):542-90. PMID: 24717572.
    View in: PubMed
  42. Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB, Bosserman LD, Burstein HJ, Cody H, Hayman J, Perkins CL, Podoloff DA, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014 May 01; 32(13):1365-83. PMID: 24663048.
    View in: PubMed
  43. Burstein HJ. Neoadjuvant pertuzumab: the exception that proves the rule? Oncology (Williston Park). 2014 Mar; 28(3):197-9. PMID: 24855726.
    View in: PubMed
  44. Burstein HJ. Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy. Am Soc Clin Oncol Educ Book. 2014; e1-3. PMID: 24857085.
    View in: PubMed
  45. Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan; 12(1):71-80. PMID: 24453294.
    View in: PubMed
  46. Krop IE, Burstein HJ. Trastuzumab: qui bono? J Natl Cancer Inst. 2013 Dec 04; 105(23):1772-5. PMID: 24262439.
    View in: PubMed
  47. Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7. PMID: 24062210.
    View in: PubMed
  48. Burstein HJ. Patients with triple negative breast cancer: is there an optimal adjuvant treatment? Breast. 2013 Aug; 22 Suppl 2:S147-8. PMID: 24074776.
    View in: PubMed
  49. Burstein HJ. Lucky to be an oncologist. J Natl Compr Canc Netw. 2013 Aug; 11(8):909-10. PMID: 23946169.
    View in: PubMed
  50. Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63. PMID: 23829891; PMCID: PMC4084778.
  51. Burstein H. Expert opinion vs guideline based care: the St. Gallen Case study. Breast. 2013 Aug; 22 Suppl 2:S1-2. PMID: 23906475.
    View in: PubMed
  52. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Jul; 11(7):753-60; quiz 761. PMID: 23847214; PMCID: PMC3991132.
  53. Burstein HJ. Breast cancer treatment in the era of individualized care. Hematol Oncol Clin North Am. 2013 Aug; 27(4):xiii-xv. PMID: 23915750.
    View in: PubMed
  54. Burstein HJ. Lou Gehrig, Angelina Jolie, and cancer genetics. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):631-2. PMID: 23744861.
    View in: PubMed
  55. Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10. PMID: 23645007.
    View in: PubMed
  56. Burstein HJ. Off-label use of oncology drugs: too much, too little, or just right? J Natl Compr Canc Netw. 2013 May 01; 11(5):505-6. PMID: 23667200.
    View in: PubMed
  57. Burstein HJ. Keeping cancer patients out of the hospital at the end of life. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):229-30. PMID: 23486448.
    View in: PubMed
  58. Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S. High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13. PMID: 23349386.
    View in: PubMed
  59. Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31. PMID: 23352568; PMCID: PMC3713786.
  60. Burstein HJ. Caring for breast cancer survivors. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):1-2. PMID: 23307974.
    View in: PubMed
  61. Burstein HJ. Measuring hope: patient expectations of chemotherapy for advanced cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1459-60. PMID: 23221783.
    View in: PubMed
  62. Gross A, Kalfin M, Partridge AH, Lane S, Burstein HJ, Fine B, Hilton N, Sullivan C, Colicchio L, Hagemeister E, Kelly A, Szabatura A, Winer EP, Mann S, Weingart S. Implementation of team training in outpatient breast oncology. J Clin Oncol. 2012 Dec; 30(34_suppl):83. PMID: 28147036.
    View in: PubMed
  63. Burstein HJ. A "shot heard 'round the world" on cancer drug costs? J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1315-6. PMID: 23138159.
    View in: PubMed
  64. Bellon JR, Wong JS, Burstein HJ. Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer? J Clin Oncol. 2012 Nov 10; 30(32):3916-20. PMID: 23032626.
    View in: PubMed
  65. Burstein HJ. Assuring access to academic cancer centers. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1177-8. PMID: 23054871.
    View in: PubMed
  66. Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78. PMID: 23001754.
    View in: PubMed
  67. Burstein HJ. Pathway-based oncology care: time for more transparency. J Natl Compr Canc Netw. 2012 Sep; 10(9):1043-4. PMID: 22956802.
    View in: PubMed
  68. Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA. Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 01; 30(28):3448-51. PMID: 22927527.
    View in: PubMed
  69. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):821-9. PMID: 22773798; PMCID: PMC3753191.
  70. Schwartz GF, Bartelink H, Burstein HJ, Cady B, Cataliotti L, Fentiman IS, Holland R, Hughes KS, Masood S, McCormick B, Palazzo JA, Pressman PI, Reis-Filho J, Pusztai L, Rutgers EJ, Seidman AD, Solin LJ, Sparano JA. Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J. 2012 Jul-Aug; 18(4):303-11. PMID: 22759093.
    View in: PubMed
  71. Burstein HJ. Simplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):797-8. PMID: 22773794.
    View in: PubMed
  72. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20; 30(21):2585-92. PMID: 22689807.
    View in: PubMed
  73. Wu AH, Lorizio W, Tchu S, Lynch K, Gerona R, Ji W, Ruan W, Ruddy KJ, Desantis SD, Burstein HJ, Ziv E. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat. 2012 Jun; 133(2):677-83. PMID: 22294487.
    View in: PubMed
  74. Burstein HJ. The top five in oncology: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 01; 10(6):681-2. PMID: 22679112.
    View in: PubMed
  75. Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82. PMID: 22614986.
    View in: PubMed
  76. Burstein HJ. If the choices are all the same, why not prefer the less-expensive option? J Natl Compr Canc Netw. 2012 Apr; 10(4):425-6. PMID: 22491041.
    View in: PubMed
  77. Burstein HJ. Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise? Nat Rev Clin Oncol. 2012 Mar 13; 9(4):191-2. PMID: 22411347.
    View in: PubMed
  78. Katz ML, Archer LE, Peppercorn JM, Kereakoglow S, Collyar DE, Burstein HJ, Schilsky RL, Partridge AH. Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5. PMID: 22392584.
    View in: PubMed
  79. Burstein HJ. Pre-judging data: benchmarking clinical significance before study results are known. J Natl Compr Canc Netw. 2012 Mar; 10(3):289-90. PMID: 22393189.
    View in: PubMed
  80. Burstein HJ. Disclosing pharma payments to oncologists: what will we learn? J Natl Compr Canc Netw. 2012 Feb; 10(2):133-4. PMID: 22308511.
    View in: PubMed
  81. Burstein HJ, Griggs JJ. Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. J Clin Oncol. 2012 Mar 01; 30(7):684-6. PMID: 22271478.
    View in: PubMed
  82. Burstein HJ. JNCCN reaches 10. J Natl Compr Canc Netw. 2012 Jan; 10(1):3. PMID: 22223863.
    View in: PubMed
  83. Pritchard KI, Bergh J, Burstein HJ. Update of the oxford overview: new insight and perspectives in the era of personalized medicine. Am Soc Clin Oncol Educ Book. 2012; 71-9. PMID: 24451712.
    View in: PubMed
  84. Burstein HJ. Avastin for breast cancer, 2005-2011: requiescat in pacem? J Natl Compr Canc Netw. 2011 Dec; 9(12):1321-3. PMID: 22157551.
    View in: PubMed
  85. Burstein HJ. The continuity of care checklist: a critical frontier in patient safety. J Natl Compr Canc Netw. 2011 Nov; 9(11):1217-8. PMID: 22056653.
    View in: PubMed
  86. Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7. PMID: 22017599.
    View in: PubMed
  87. Burstein HJ. Patients with anti-HER2 responsive disease: definition and adjuvant therapies. Breast. 2011 Oct; 20 Suppl 3:S132-4. PMID: 22015280.
    View in: PubMed
  88. Burstein HJ. Have we been down this road before? J Natl Compr Canc Netw. 2011 Sep 01; 9(9):953. PMID: 21917620.
    View in: PubMed
  89. Ajani JA, Mangu PB, Burstein HJ. Peek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9. PMID: 22211134; PMCID: PMC3170070.
  90. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30. PMID: 21788567.
    View in: PubMed
  91. Burstein HJ. The fifth "C" is cost: highlights from ASCO 2011. J Natl Compr Canc Netw. 2011 Jul 01; 9(7):691. PMID: 21715720.
    View in: PubMed
  92. Punglia RS, Burstein HJ, Weeks JC. Radiation therapy for ductal carcinoma in situ: a decision analysis. Cancer. 2012 Feb 01; 118(3):603-11. PMID: 21720992; PMCID: PMC3189439.
  93. Munzone E, Curigliano G, Burstein HJ, Winer EP, Goldhirsch A. CMF revisited in the 21st century. Ann Oncol. 2012 Feb; 23(2):305-11. PMID: 21715566.
    View in: PubMed
  94. Dominici L, Najita J, Hughes M, Niland J, Marcom P, Wong YN, Carter B, Javid S, Edge S, Burstein H, Golshan M. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):459-65. PMID: 21713372; PMCID: PMC3382105.
  95. Burstein HJ. Novel agents and future directions for refractory breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S17-24. PMID: 21600381.
    View in: PubMed
  96. Burstein HJ. Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S1-2. PMID: 21600379.
    View in: PubMed
  97. Gropper A, Burstein HJ, Harris L, Anderson KS, Gold JM, Younger WJ, Bunnell CA, Najita JS, Winer EP, Mayer EL. Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e11074. PMID: 28023110.
    View in: PubMed
  98. Perez E, Burstein HJ, Hudis C. Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol. 2011 May; 9(5 Suppl 11):1-16. PMID: 21738119.
    View in: PubMed
  99. Burstein HJ. Texting the doctor. J Natl Compr Canc Netw. 2011 May; 9(5):459. PMID: 21550965.
    View in: PubMed
  100. Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJ. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-7. PMID: 21531783; PMCID: PMC3276325.
  101. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011 Jul; 58(1):85-92. PMID: 21482957; PMCID: PMC4586117.
  102. Burstein HJ. Mind the gap. J Natl Compr Canc Netw. 2011 Apr; 9(4):343. PMID: 21464142.
    View in: PubMed
  103. Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJ. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011 Dec; 22(12):2582-90. PMID: 21406472.
    View in: PubMed
  104. Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol. 2011 Apr 01; 29(10):1232-5. PMID: 21383305.
    View in: PubMed
  105. Lin NU, Burstein HJ. EMBRACE, eribulin, and new realities of advanced breast cancer. Lancet. 2011 Mar 12; 377(9769):878-80. PMID: 21376386.
    View in: PubMed
  106. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9. PMID: 21324674; PMCID: PMC4211594.
  107. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive breast cancer. J Natl Compr Canc Netw. 2011 Feb; 9(2):136-222. PMID: 21310842.
    View in: PubMed
  108. Burstein HJ. Take your medicine. J Natl Compr Canc Netw. 2011 Feb; 9 Suppl 3:S1. PMID: 21357661.
    View in: PubMed
  109. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8. PMID: 21205755.
    View in: PubMed
  110. Burstein HJ. Beaten at the Alamo by the Europeans. J Natl Compr Canc Netw. 2011 Jan; 9(1):1. PMID: 21233239.
    View in: PubMed
  111. Burstein HJ. Board recertification. J Natl Compr Canc Netw. 2010 Oct; 8(10):1111. PMID: 20971837.
    View in: PubMed
  112. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207. PMID: 20971842.
    View in: PubMed
  113. Burstein HJ. Addressing oncology pharmacy & policy. J Natl Compr Canc Netw. 2010 Sep; 8 Suppl 7:S1. PMID: 20947719.
    View in: PubMed
  114. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104. PMID: 20728696.
    View in: PubMed
  115. Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010 Sep; 6(5):243-6. PMID: 21197188; PMCID: PMC2936467.
  116. Burstein HJ. Avastin, ODAC, and the FDA: are we drafting the right players? J Natl Compr Canc Netw. 2010 Aug; 8(8):833-4. PMID: 20870630.
    View in: PubMed
  117. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3784-96. PMID: 20625130.
    View in: PubMed
  118. Burstein HJ, Griggs JJ. Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 2010 Jul; 19(3):639-47. PMID: 20620932.
    View in: PubMed
  119. Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, Qamar R, Volterra F, Parmar H, Samant M, Burstein HJ. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-6. PMID: 20497961.
    View in: PubMed
  120. Burstein HJ. Re-engineering the cooperative groups. J Natl Compr Canc Netw. 2010 May; 8(5):505. PMID: 20495080.
    View in: PubMed
  121. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010 Mar 10; 28(8):1301-7. PMID: 20142587.
    View in: PubMed
  122. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1124-30. PMID: 20124187.
    View in: PubMed
  123. Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 01; 27(34):5671-3. PMID: 19884535.
    View in: PubMed
  124. Burstein HJ. Screening contretemps: the real issue in the mammogram guideline debate. J Natl Compr Canc Netw. 2009 Nov; 7(10):1039-40. PMID: 19930972.
    View in: PubMed
  125. Burstein HJ. What is a patient navigator, and should we have them in major cancer centers? J Natl Compr Canc Netw. 2009 Oct; 7(9):905. PMID: 19878636.
    View in: PubMed
  126. Burstein HJ. Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age. Breast. 2009 Oct; 18 Suppl 3:S135-6. PMID: 19914532.
    View in: PubMed
  127. Burstein HJ. Colon cancer: the new breast cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):773. PMID: 19755044.
    View in: PubMed
  128. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3. PMID: 19755043.
    View in: PubMed
  129. Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, Junck L, Morris GS, Paice JA, Tummala S, Von Roenn JH. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 5:S1-S26; quiz S27-8. PMID: 19755042.
    View in: PubMed
  130. Burstein HJ, Souter I, D'Alessandro HA, Sgroi DC. Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer. N Engl J Med. 2009 Aug 13; 361(7):699-707. PMID: 19675333.
    View in: PubMed
  131. Abel GA, Burstein HJ, Hevelone ND, Weeks JC. Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol. 2009 Sep 01; 27(25):4182-7. PMID: 19652071; PMCID: PMC4881368.
  132. Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009 Nov; 20(11):1771-85. PMID: 19608616.
    View in: PubMed
  133. Burstein HJ. Quality measures, clinical practice, NCCN, and McAllen, Texas. J Natl Compr Canc Netw. 2009 Jul; 7(7):695. PMID: 19635224.
    View in: PubMed
  134. Gold JM, Najita JS, Lester S, Richardson AL, Morganstern DE, Chen WY, Partridge AH, Krop IE, Winer EP, Burstein HJ. Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. J Clin Oncol. 2009 May 20; 27(15_suppl):572. PMID: 27960736.
    View in: PubMed
  135. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65. PMID: 19439741; PMCID: PMC3082436.
  136. Burstein HJ. By the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting breast cancer as a regular mammogram? Harv Health Lett. 2009 May; 34(7):2. PMID: 19562852.
    View in: PubMed
  137. Burstein HJ. Do clinical trials belong in clinical guidelines? J Natl Compr Canc Netw. 2009 May; 7(5):489. PMID: 19460277.
    View in: PubMed
  138. Burstein HJ. SPIKES for difficult conversations with cancer patients. J Natl Compr Canc Netw. 2009 Apr; 7(4):341. PMID: 19406038.
    View in: PubMed
  139. Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23. PMID: 19294501; PMCID: PMC4578795.
  140. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92. PMID: 19200416.
    View in: PubMed
  141. Burstein HJ. Personalized medicine and breast cancer care. J Natl Compr Canc Netw. 2009 Feb; 7(2):109. PMID: 19241643.
    View in: PubMed
  142. Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009 Jun; 20(6):1026-31. PMID: 19179558.
    View in: PubMed
  143. Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009 Jan-Mar; 24(1):1-10. PMID: 19404916.
    View in: PubMed
  144. Cirelli JA, Park CH, MacKool K, Taba M, Lustig KH, Burstein H, Giannobile WV. AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression. Gene Ther. 2009 Mar; 16(3):426-36. PMID: 19078994; PMCID: PMC2656404.
  145. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7. PMID: 19047116.
    View in: PubMed
  146. Burstein H. Updates in anti-HER2 combination therapy. Clin Adv Hematol Oncol. 2008 Dec; 6(12):873-4. PMID: 19209136.
    View in: PubMed
  147. Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20; 26(36):5994-6000. PMID: 19029413.
    View in: PubMed
  148. Gold JM, Burstein HJ. Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity. Oncology (Williston Park). 2008 Nov 15; 22(12):1416, 1424. PMID: 19322949.
    View in: PubMed
  149. Burstein HJ. Conflict of interest and oncology guidelines. J Natl Compr Canc Netw. 2008 Nov; 6(10):955. PMID: 19186396.
    View in: PubMed
  150. Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2. PMID: 18926092.
    View in: PubMed
  151. Burstein HJ. Oncology teamwork. J Natl Compr Canc Netw. 2008 Sep; 6(8):715. PMID: 18939346.
    View in: PubMed
  152. Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008 Aug; 8(4):352-6. PMID: 18757263.
    View in: PubMed
  153. Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12. PMID: 18581232.
    View in: PubMed
  154. Abel GA, Hevelone ND, Burstein HJ, Weeks JC. Cancer-related direct-to-consumer advertising: awareness, perceived impact, and associated patient and provider behavior. J Clin Oncol. 2008 May 20; 26(15_suppl):6631. PMID: 27949350.
    View in: PubMed
  155. Mayer EL, Miller KD, Rugo HS, Peppercorn JM, Carey LA, Ryabin N, Josephs K, Winer EP, Burstein HJ. A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):519. PMID: 27948554.
    View in: PubMed
  156. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):1015. PMID: 27951344.
    View in: PubMed
  157. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 May 07; 100(9):642-8. PMID: 18445827; PMCID: PMC2864146.
  158. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9. PMID: 18421051; PMCID: PMC4524351.
  159. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9. PMID: 18375893.
    View in: PubMed
  160. Burstein HJ. Preoperative therapy as a model for translational research in breast cancer. Cancer Invest. 2008 Apr-May; 26(3):217-21. PMID: 18317961.
    View in: PubMed
  161. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6. PMID: 18347007.
    View in: PubMed
  162. Mayer EL, Burstein HJ. Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1198-200. PMID: 18323544.
    View in: PubMed
  163. Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KL. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008 Jun; 19(6):1068-74. PMID: 18283035.
    View in: PubMed
  164. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9. PMID: 18258991.
    View in: PubMed
  165. Burstein HJ, Schwartz RS. Molecular origins of cancer. N Engl J Med. 2008 Jan 31; 358(5):527. PMID: 18234758.
    View in: PubMed
  166. Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25; quiz S26-7. PMID: 18597715.
    View in: PubMed
  167. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep 01; 25(25):3797-9. PMID: 17761968.
    View in: PubMed
  168. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 01; 110(5):965-72. PMID: 17614302.
    View in: PubMed
  169. Burstein HJ. Cognitive side-effects of adjuvant treatments. Breast. 2007 Dec; 16 Suppl 2:S166-8. PMID: 17719225.
    View in: PubMed
  170. Podoloff DA, Advani RH, Allred C, Benson AB, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW, Hillner BE, Hoffman JM, Kiel K, Komaki R, Larson SM, Mankoff DA, Rosenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007 May; 5 Suppl 1:S1-22; quiz S23-2. PMID: 17509259.
    View in: PubMed
  171. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):257-72. PMID: 17512448.
    View in: PubMed
  172. Burstein HJ. Anemia in cancer: update on studies of erythropoiesis-stimulating agents. J Support Oncol. 2007 Apr; 5(4 Suppl 2):5-26. PMID: 17550053.
    View in: PubMed
  173. Burstein HJ. Biological basis of breast cancer: an introduction. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S1-3. PMID: 17512430.
    View in: PubMed
  174. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007 Jun; 16(3):223-34. PMID: 17368903.
    View in: PubMed
  175. Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75. PMID: 17345004.
    View in: PubMed
  176. Mayer EL, Lin NU, Burstein HJ. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw. 2007 Mar; 5(3):314-23. PMID: 17439759.
    View in: PubMed
  177. Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312. PMID: 17439758.
    View in: PubMed
  178. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207. PMID: 17317830.
    View in: PubMed
  179. Mayer EL, Carey LA, Burstein HJ. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007; 9(5):110. PMID: 17888189; PMCID: PMC2242653.
  180. Burstein HJ. Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. Oncology (Williston Park). 2006 Dec; 20(14 Suppl 9):13-5. PMID: 17370924.
    View in: PubMed
  181. Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5330-1. PMID: 17114668.
    View in: PubMed
  182. Sledge GW, Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. PMID: 17139244.
    View in: PubMed
  183. Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4. PMID: 16969707.
    View in: PubMed
  184. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007 Feb; 18(2):215-25. PMID: 16831851.
    View in: PubMed
  185. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4. PMID: 16813731.
    View in: PubMed
  186. Deprimo SE, Friece C, Huang X, Smeraglia J, Sherman L, Collier M, Baum C, Elias AD, Burstein HJ, Miller KD. Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):578. PMID: 27953751.
    View in: PubMed
  187. Burstein HJ, Keshaviah A, Baron A, Hart R, Lambert-Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):650. PMID: 27952232.
    View in: PubMed
  188. Peppercorn J, Joffe S, Burstein HJ, Winer E. Use of experimental therapy outside of clinical trials among U.S. oncologists. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6047. PMID: 27954839.
    View in: PubMed
  189. Mayer EL, Harris LN, Partridge AH, Gelman RS, Schumer ST, Comanaru RS, Long M, Sampson E, Burstein HJ, Winer EP. Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10564. PMID: 27952013.
    View in: PubMed
  190. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006 Jun 15; 106(12):2576-82. PMID: 16703595.
    View in: PubMed
  191. Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006 Jun; 7(2):158-61. PMID: 16800976.
    View in: PubMed
  192. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26. PMID: 16507275.
    View in: PubMed
  193. Peppercorn J, Partridge A, Burstein HJ, Winer EP. Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8. PMID: 16288876.
    View in: PubMed
  194. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7. PMID: 16293865.
    View in: PubMed
  195. Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504. PMID: 16243442.
    View in: PubMed
  196. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20; 353(16):1652-4. PMID: 16236735.
    View in: PubMed
  197. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30):7703-20. PMID: 16157938.
    View in: PubMed
  198. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7. PMID: 16150805.
    View in: PubMed
  199. Burstein HJ. Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA. Expert Rev Anticancer Ther. 2005 Aug; 5(4):581-3. PMID: 16111459.
    View in: PubMed
  200. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005 Aug 01; 23(22):5178-87. PMID: 15998905.
    View in: PubMed
  201. Burstein HJ, Winer EP, Kuntz KM, Weeks JC, Punglia RS. Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):529. PMID: 27946407.
    View in: PubMed
  202. Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol. 2005 Jun; 23(16_suppl):563. PMID: 27946470.
    View in: PubMed
  203. Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89. PMID: 16002000.
    View in: PubMed
  204. Burstein HJ, Winer EP. HER2 or not HER2: that is the question. J Clin Oncol. 2005 Jun 01; 23(16):3656-9. PMID: 15738533.
    View in: PubMed
  205. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29. PMID: 15545664.
    View in: PubMed
  206. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004 Sep 01; 22(17):3631-8. PMID: 15289488.
    View in: PubMed
  207. Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):547. PMID: 28016577.
    View in: PubMed
  208. Baselga J, Fumoleau P, Gil M, Colomer R, Roche H, Cortes-Funes H, Burstein H, Kaufman P, Kong S, Moore L. Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. J Clin Oncol. 2004 Jul 15; 22(14_suppl):544. PMID: 28016595.
    View in: PubMed
  209. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004 Apr 01; 350(14):1430-41. PMID: 15070793.
    View in: PubMed
  210. Partridge AH, Winer EP, Burstein HJ. Follow-up care of breast cancer survivors. Semin Oncol. 2003 Dec; 30(6):817-25. PMID: 14663782.
    View in: PubMed
  211. Spigel DR, Burstein HJ. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2003 Dec; 4(5):329-37; discussion 338-9. PMID: 14715107.
    View in: PubMed
  212. Burstein HJ. Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer. N Engl J Med. 2003 Nov 06; 349(19):1857-9. PMID: 14551340.
    View in: PubMed
  213. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95. PMID: 12885806.
    View in: PubMed
  214. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7. PMID: 12784331.
    View in: PubMed
  215. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7. PMID: 12846423.
    View in: PubMed
  216. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9. PMID: 12732612.
    View in: PubMed
  217. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51. PMID: 12697865.
    View in: PubMed
  218. Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2. PMID: 12644548.
    View in: PubMed
  219. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53. PMID: 12506169.
    View in: PubMed
  220. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 01; 20(15):3328-43. PMID: 12149307.
    View in: PubMed
  221. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27. PMID: 12149306.
    View in: PubMed
  222. Jeter MD, Jänne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, Loeffler JS, Devlin PM, Salgia R. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400. PMID: 12023144.
    View in: PubMed
  223. Burstein HJ, Partridge AH, Lesnikoski BA. Treatment of breast cancer during pregnancy. Expert Opin Pharmacother. 2002 Apr; 3(4):423-8. PMID: 11934346.
    View in: PubMed
  224. Spigel DR, Burstein HJ. HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol. 2002 Apr; 3(2):163-74. PMID: 12057079.
    View in: PubMed
  225. Burstein HJ, Bunnell CA, Winer EP. New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58. PMID: 11498829.
    View in: PubMed
  226. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30. PMID: 11352965.
    View in: PubMed
  227. Burstein HJ, Swanson SJ, Christian RL, McMenamin ME. Unusual aspects of breast cancer: case 2. Synchronous bilateral lung and breast cancers. J Clin Oncol. 2001 May 01; 19(9):2571-3. PMID: 11331338.
    View in: PubMed
  228. Winer EP, Burstein HJ. New combinations with Herceptin in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:50-7. PMID: 11694788.
    View in: PubMed
  229. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30):135-42. PMID: 11773307.
    View in: PubMed
  230. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94. PMID: 11027744.
    View in: PubMed
  231. Burstein HJ. Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol. 2000 Jul; 18(13):2501-4. PMID: 10893279.
    View in: PubMed
  232. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9. PMID: 10715290.
    View in: PubMed
  233. Burstein HJ. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol. 2000 Feb; 18(3):693-4. PMID: 10653885.
    View in: PubMed
  234. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6. PMID: 10572612.
    View in: PubMed
  235. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999 Jun 03; 340(22):1733-9. PMID: 10352166.
    View in: PubMed
  236. Burstein HJ, Janicek MJ, Skarin AT. Hypertrophic osteoarthropathy. J Clin Oncol. 1997 Jul; 15(7):2759-60. PMID: 9215850.
    View in: PubMed
  237. Cameron CE, Burstein H, Bizub-Bender D, Ridky T, Weber IT, Wlodawer A, Skalka AM, Leis J. Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency. Adv Exp Med Biol. 1995; 362:399-406. PMID: 8540349.
    View in: PubMed
  238. Cameron CE, Ridky TW, Shulenin S, Leis J, Weber IT, Copeland T, Wlodawer A, Burstein H, Bizub-Bender D, Skalka AM. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J Biol Chem. 1994 Apr 15; 269(15):11170-7. PMID: 8157644.
    View in: PubMed
  239. Abbas AK, Burstein HJ, Bogen SA. Determinants of helper T cell-dependent antibody production. Semin Immunol. 1993 Dec; 5(6):441-7. PMID: 8123797.
    View in: PubMed
  240. Burstein HJ, Abbas AK. In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J Exp Med. 1993 Feb 01; 177(2):457-63. PMID: 8426114; PMCID: PMC2190921.
  241. Vogt VM, Burstein H, Skalka AM. Proteolysis in the maturation of avian retroviruses does not require calcium. Virology. 1992 Aug; 189(2):771-4. PMID: 1322601.
    View in: PubMed
  242. Burstein HJ, Shea CM, Abbas AK. Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. J Immunol. 1992 Jun 15; 148(12):3687-91. PMID: 1534821.
    View in: PubMed
  243. Grinde B, Cameron CE, Leis J, Weber IT, Wlodawer A, Burstein H, Skalka AM. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem. 1992 May 15; 267(14):9491-8. PMID: 1315756.
    View in: PubMed
  244. Grinde B, Cameron CE, Leis J, Weber IT, Wlodawer A, Burstein H, Bizub D, Skalka AM. Mutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem. 1992 May 15; 267(14):9481-90. PMID: 1315755.
    View in: PubMed
  245. Burstein H, Bizub D, Kotler M, Schatz G, Vogt VM, Skalka AM. Processing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site. J Virol. 1992 Mar; 66(3):1781-5. PMID: 1310781; PMCID: PMC240938.
  246. Burstein H, Bizub D, Skalka AM. Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol. 1991 Nov; 65(11):6165-72. PMID: 1656090; PMCID: PMC250303.
  247. Burstein HJ, Tepper RI, Leder P, Abbas AK. Humoral immune functions in IL-4 transgenic mice. J Immunol. 1991 Nov 01; 147(9):2950-6. PMID: 1919000.
    View in: PubMed
  248. Abbas AK, Williams ME, Burstein HJ, Chang TL, Bossu P, Lichtman AH. Activation and functions of CD4+ T-cell subsets. Immunol Rev. 1991 Oct; 123:5-22. PMID: 1684783.
    View in: PubMed
  249. Burstein HJ, Abbas AK. T-cell-mediated activation of B cells. Curr Opin Immunol. 1991 Jun; 3(3):345-9. PMID: 1716914.
    View in: PubMed
  250. Dohnal JC, Bowie LJ, Burstein HJ. Functional phospholipid/sphingomyelin ratio: an easy to interpret indicator of fetal lung maturity. Ann Clin Lab Sci. 1986 Sep-Oct; 16(5):407-11. PMID: 3777858.
    View in: PubMed
  251. Dohnal JC, Bowie LJ, Burstein HJ. Degree of unsaturation of the fatty acid chains of phospholipids influences the fluorescence polarization: implications for evaluating fetal lung maturity. Clin Chem. 1986 Mar; 32(3):425-8. PMID: 3753910.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Burstein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_